Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma

Simple item page
dc.contributor.authorBilaç C.
dc.contributor.authorMüezzinoǧlu T.
dc.contributor.authorErmertcan A.T.
dc.contributor.authorKayhan T.C.
dc.contributor.authorTemeltaş G.
dc.contributor.authorÖzütrkcan S.
dc.contributor.authorTemiz P.
dc.date.accessioned2024-07-22T08:21:29Z
dc.date.available2024-07-22T08:21:29Z
dc.date.issued2009
dc.description.abstractSorafenib is a new therapeutic agent being used in metastatic renal cell carcinoma, hepatocellular carcinoma, and malignant melanoma. The most frequently seen cutaneous side effects due to sorafenib are erythema, exfoliative dermatitis, acne vulgaris, and flushing. Folliculitis, eczema, and erythema multiforme are other, rare side effects of sorafenib. A 59-year-old man underwent left radical nephrectomy due to renal cell carcinoma 8 months ago, and after the operation he received immunochemotherapy and then sorafenib. On the third day of sorafenib therapy his lesions occurred. His dermatologic examination revealed multiple erythematous papules on his neck, arms, and legs and bullae and iris lesions on his palms and soles. He was diagnosed as having erythema multiforme. In the literature we found only 1 other erythema multiforme case due to sorafenib. We present this interesting case to show and discuss cutaneous side effects of sorafenib, especially erythema multiforme as a very rare cutaneous side effect. © 2009 Informa UK Ltd.
dc.identifier.DOI-ID10.1080/15569520902915469
dc.identifier.issn15569535
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18639
dc.language.isoEnglish
dc.subjectAntineoplastic Agents
dc.subjectBenzenesulfonates
dc.subjectCarcinoma, Renal Cell
dc.subjectDose-Response Relationship, Drug
dc.subjectErythema Multiforme
dc.subjectHumans
dc.subjectKidney Neoplasms
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPyridines
dc.subjectTreatment Outcome
dc.subjectSoleidae
dc.subjectcorticosteroid
dc.subjectpermanganate potassium
dc.subjectsorafenib
dc.subjectantineoplastic agent
dc.subjectbenzenesulfonic acid derivative
dc.subjectpyridine derivative
dc.subjectsorafenib
dc.subjectadult
dc.subjectarm
dc.subjectarticle
dc.subjectblister
dc.subjectcancer chemotherapy
dc.subjectcase report
dc.subjectdrug dose reduction
dc.subjectdrug withdrawal
dc.subjecterythema multiforme
dc.subjectexocytosis
dc.subjectfoot sole
dc.subjecthand palm
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectimmunotherapy
dc.subjectiris
dc.subjectkidney carcinoma
dc.subjectleg
dc.subjectmale
dc.subjectmetastasis
dc.subjectmultimodality cancer therapy
dc.subjectneck
dc.subjectnephrectomy
dc.subjectoutpatient department
dc.subjectpapule
dc.subjectpatient referral
dc.subjectskin biopsy
dc.subjectskin examination
dc.subjecttreatment duration
dc.subjectchemically induced disorder
dc.subjectdose response
dc.subjecterythema multiforme
dc.subjectkidney tumor
dc.subjectmiddle aged
dc.subjecttreatment outcome
dc.titleSorafenib-induced erythema multiforme in metastatic renal cell carcinoma
dc.typeArticle

Files

Collections

Scopus Koleksiyonu